🏥Medicare IPPS FY 2026 Regulations
This final rule revises the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; makes changes relating to Medicare graduate medical education (GME) for teaching hospitals; updates the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); updates and makes changes to requirements for certain quality programs; and makes other policy- related changes. We are also finalizing the provisions of the interim final action with comment period regarding the changes to the FY 2025 IPPS rates due to the court decision in Bridgeport Hosp. v. Becerra. Lastly, it finalizes certain updates to the ONC Health Information Technology (IT) Certification Program.
Learn More🏥Correction Notice for CMS Information Collection Request
On June 20, 2025, CMS published a notice in the Federal Register that sought comment on a collection of information concerning CMS-10846 (OMB control number 0938-1451) entitled "Medicare Part D Manufacturer Discount Program." The point of contact information is incorrectly listed in the last sentence within the last paragraph of the notice. This document corrects the error.
Learn More💰Proposed Updates to ESRD Payment System Impacting Business
This proposed rule would update and revise the End-Stage Renal Disease (ESRD) Prospective Payment System for calendar year 2026. This rule also proposes to update the payment rate for renal dialysis services furnished by an ESRD facility to individuals with acute kidney injury. In addition, this rule proposes to update requirements for the ESRD Quality Incentive Program and to terminate and modify requirements for the ESRD Treatment Choices Model.
Learn More⚖️DEA Revokes Registration for Improper Controlled Substance Prescribing
The Drug Enforcement Administration (DEA) issued a revocation order for Margaret Dennis, D.M.D., for improper prescribing of controlled substances, citing numerous violations of federal and state laws. The findings include lack of medical justification, inadequate record-keeping, and failure to monitor potential abuse, highlighting significant compliance issues within the healthcare sector.
Learn More⚖️DEA Revokes Registration of Texas Practitioner
The Drug Enforcement Administration has revoked the DEA registration of Willard J. Davis, D.O., due to his lack of authority to handle controlled substances in Texas following the suspension of his medical license. The decision emphasizes the need for practitioners to possess valid licenses to maintain DEA registration.
Learn More